MedTrace Logo

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-05-04

No results posted yet for this study

Summary

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.

Conditions

Interventions

DRUG

Cevostamab

Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles. Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.

DRUG

Lenalidomide

Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.

DRUG

Tocilizumab

Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

DRUG

Iberdomide

Iberdomide will be administered PO on days 1-14 of a 21-day cycle.

DRUG

Dexamethasone

Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-14
Primary Completion
2028-07-31
Completion
2028-07-31
FDA Drug
Yes

Countries

  • Australia
  • France
  • Germany
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05583617 on ClinicalTrials.gov